Summit Therapeutics (SMMT) Free Cash Flow (2020 - 2025)
Summit Therapeutics' Free Cash Flow history spans 6 years, with the latest figure at -$101.7 million for Q4 2025.
- For Q4 2025, Free Cash Flow fell 108.42% year-over-year to -$101.7 million; the TTM value through Dec 2025 reached -$323.2 million, down 127.23%, while the annual FY2025 figure was -$323.2 million, 127.23% down from the prior year.
- Free Cash Flow reached -$101.7 million in Q4 2025 per SMMT's latest filing, down from -$93.5 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $5.2 million in Q4 2022 to a low of -$101.7 million in Q4 2025.
- Average Free Cash Flow over 5 years is -$32.9 million, with a median of -$22.1 million recorded in 2021.
- Peak YoY movement for Free Cash Flow: surged 155.93% in 2022, then crashed 474.18% in 2023.
- A 5-year view of Free Cash Flow shows it stood at -$9.3 million in 2021, then soared by 155.93% to $5.2 million in 2022, then plummeted by 474.18% to -$19.5 million in 2023, then crashed by 150.82% to -$48.8 million in 2024, then crashed by 108.42% to -$101.7 million in 2025.
- Per Business Quant, the three most recent readings for SMMT's Free Cash Flow are -$101.7 million (Q4 2025), -$93.5 million (Q3 2025), and -$66.4 million (Q2 2025).